Literature DB >> 29971459

[Perioperative management for CRS and HIPEC : Anesthesiological aspects].

D Bleiler1, S Bleiler1, B Sinner2.   

Abstract

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are therapeutic options for the treatment of intra-abdominal neoplasms. Following the resection of all visible tumor areas by CRS, microscopic tumor areas are treated with HIPEC. This procedure increases the quality of life and survival. The CRS with HIPEC is a complex surgical procedure in which the mainly younger and often otherwise healthy patients undergo several pathophysiological changes during the operation. The main concern of the anesthesiologist is the massive volume loss, volume shift and metabolic alterations. Patients with a high comorbidity should undergo preoperative optimization to reduce the perioperative morbidity and mortality especially by protracted interventions.

Entities:  

Keywords:  Abdominal neoplasms; Anesthesiology; Coagulation management; Postoperative analgesia; Volume management

Mesh:

Year:  2018        PMID: 29971459     DOI: 10.1007/s00104-018-0677-3

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  33 in total

Review 1.  Management of mechanical ventilation during laparoscopic surgery.

Authors:  Franco Valenza; Giorgio Chevallard; Tommaso Fossali; Valentina Salice; Marta Pizzocri; Luciano Gattinoni
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2010-06

2.  Volume therapy and cardiocircular function during hyperthermic intraperitoneal chemotherapy.

Authors:  W Raue; N Tsilimparis; A Bloch; C Menenakos; J Hartmann
Journal:  Eur Surg Res       Date:  2009-10-17       Impact factor: 1.745

Review 3.  Anaesthetic Considerations in the Perioperative Management of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Deepak B Sheshadri; Murali R Chakravarthy
Journal:  Indian J Surg Oncol       Date:  2016-02-20

4.  Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C.

Authors:  Natasha M Rueth; Sara E Murray; Stephen J Huddleston; Andrea M Abbott; Edward W Greeno; Mark N Kirstein; Todd M Tuttle
Journal:  Ann Surg Oncol       Date:  2010-07-08       Impact factor: 5.344

5.  Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy.

Authors:  Federico Piccioni; Claudia Casiraghi; Luca Fumagalli; Shigeki Kusamura; Dario Baratti; Marcello Deraco; Flavio Arienti; Martin Langer
Journal:  Int J Surg       Date:  2015-03-11       Impact factor: 6.071

6.  Cardiovascular changes during continuous hyperthermic peritoneal perfusion.

Authors:  N Shime; M Lee; T Hatanaka
Journal:  Anesth Analg       Date:  1994-05       Impact factor: 5.108

7.  Risk factors for acute lung injury after thoracic surgery for lung cancer.

Authors:  Marc Licker; Marc de Perrot; Anastase Spiliopoulos; John Robert; John Diaper; Catherine Chevalley; Jean-Marie Tschopp
Journal:  Anesth Analg       Date:  2003-12       Impact factor: 5.108

8.  Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.

Authors:  Shigeki Kusamura; Dario Baratti; Rami Younan; Barbara Laterza; Grazia Daniela Oliva; Pasqualina Costanzo; Myriam Favaro; Cecilia Gavazzi; Federica Grosso; Marcello Deraco
Journal:  Ann Surg Oncol       Date:  2007-06-09       Impact factor: 5.344

9.  Balanced crystalloid compared with balanced colloid solution using a goal-directed haemodynamic algorithm.

Authors:  A Feldheiser; V Pavlova; T Bonomo; A Jones; C Fotopoulou; J Sehouli; K-D Wernecke; C Spies
Journal:  Br J Anaesth       Date:  2012-10-30       Impact factor: 9.166

10.  Post-operative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC).

Authors:  Timothy J Cooksley; Philip Haji-Michael
Journal:  World J Surg Oncol       Date:  2011-12-19       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.